ReproCell Stock

ReproCell FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of ReproCell (4978.T) as of Sep 4, 2026 is -77.87 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 582.17 % — a change of -113.38% (lower).

FCF Conversion

-77.87 %

YoY

-113.38%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of ReproCell is 2026 -77.87 % . FCF Conversion Rate (FCF/EBITDA) of ReproCell was 2025 582.17 % . It decreases by -113.38% lower compared to the previous year.

The ReproCell FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
31.31 JPY
Jan 1, 2019
107.54 JPY
Jan 1, 2020
79.68 JPY
Jan 1, 2021
87.22 JPY
Jan 1, 2022
50.37 JPY
Jan 1, 2023
95.29 JPY
Jan 1, 2024
582.17 JPY
Jan 1, 2025
-77.87 JPY
The ReproCell FCF Conversion history
YEARFCF ConversionYoY
-77.87 %-113.38%
582.17 %+510.97%
95.29 %+89.19%
50.37 %-42.26%
87.22 %+9.47%
79.68 %-25.91%
107.54 %+243.46%
31.31 %-66.04%
92.20 %+181.02%
32.81 %-77.49%
145.78 %+365.20%
31.34 %
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

FCF Conversion Rate (FCF/EBITDA) of ReproCell is -77.87 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of ReproCell changed from 582.17 % to -77.87 %, representing a -113.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) ReproCell since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s ReproCell with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — ReproCell

All Key Metrics — ReproCell